floxuridine
Commercial- Indications
- Colorectal cancer liver metastases, Intrahepatic cholangiocarcinoma
Company intelligence / Profile preview
The Intera 3000 Hepatic Artery Infusion Pump enables continuous local delivery of floxuridine to liver tumors. Clinical data show that HAI therapy improves tumor response rates, time to progression, and overall survival compared to systemic chemotherapy alone. Combining HAI with systemic chemotherapy can extend survival and increase conversion-to-resection rates for patients with unresectable or resected colorectal liver metastases. Current clinical trials are evaluating broader use cases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Intera Oncology.